Normobaric hypoxia (LHTL)
OtherParticipants lived in normobaric hypoxic rooms for 14-16 h per day while completing their regular training under normoxic conditions. The simulated altitude was progressively increased during the intervention.
NCT Number: NCT06264193
The response to hypoxia is very individual and depending on many aspects, such as the type of training, duration, intensity, or hypoxic stimulus, hypoxia affects the athlete in various ways. This multi-stage study investigated hematological and physiological responses to normobaric Live High-Train Low (LHTL) exposure in elite male rowers from the Polish national rowing team. Stage I evaluated responses during an 18-day LHTL intervention, whereas Stage II evaluated responses during a 14-day LHTL intervention and extended the assessment to 42 days after return to normoxia. The study focused particularly on hematological variables, erythropoietin (EPO), vascular endothelial growth factor (VEGF), and other physiological and biochemical responses associated with hypoxic exposure.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Not applicable
I stage. The Polish national rowing team athletes, 13 males, were randomly divided into two groups:
II stage. Fourteen elite male rowers from the Polish national rowing team participated in the second stage and were randomly allocated to the LHTL group (n = 8) or the normoxic control group (n = 6). Both groups followed the same standardized training program. The LHTL intervention lasted 14 consecutive days and involved progressive normobaric hypoxic exposure corresponding to 2000-3000 m for approximately 14-16 h/day, while all training sessions were performed under normoxic conditions. Blood samples were collected at baseline, after 7 and 14 days of the intervention, and 8, 14, and 42 days after completion. Hematological variables, EPO, VEGF, iron-related indices, CK activity, and lipid-profile variables were assessed, while SpO₂ and resting HR were monitored throughout the intervention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants lived in normobaric hypoxic rooms for 14-16 h per day while completing their regular training under normoxic conditions. The simulated altitude was progressively increased during the intervention.
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
immunoenzymatic assay methods using diagnostic kits
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
immunoenzymatic assay methods using diagnostic kits
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
was determined using spectrophotometer analysis and diagnostic kits
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention.
was determined by immunoenzymatic assay methods using diagnostic kits
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
A professional accredited laboratory company determined the Hb level (Poland, ISO 9001:2008).
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
A professional accredited laboratory company determined the Htc level (Poland, ISO 9001:2008).
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
A professional accredited laboratory company determined the RBC level (Poland, ISO 9001:2008).
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
A professional accredited laboratory company determined the WBC level (Poland, ISO 9001:2008).
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
A professional accredited laboratory company determined the Ret level (Poland, ISO 9001:2008).
Time frame: Stage 1: daily from Day 1 through Day 18 of the intervention, in the morning after waking and in the evening before bedtime; Stage 2: daily from Day 1 through Day 14 of the intervention, in the morning after waking and in the evening before bedtime.
Peripheral oxygen saturation (SpO₂) was measured non-invasively using a pulse oximeter (Tech-Med, ISO 13485). Measurements were performed twice daily, in the morning and evening, throughout each sports camp in both study groups.
Time frame: Stage 1: daily from Day 1 through Day 18 of the intervention; Stage 2: daily from Day 1 through Day 14 of the intervention.
Heart rate (HR) was measured using a pulse oximeter (Tech-Med, ISO 13485). Measurements were performed twice daily, in the morning and evening, throughout each sports camp in both study groups.
Time frame: Stage 1: baseline and Days 6, 12, and 18 of the intervention; Stage 2: baseline and Days 7 and 14 of the intervention, and 8, 14, and 42 days after the intervention.
Body mass was assessed using a multi-frequency bioelectrical impedance analyzer (TANITA MC-780MA). Measurements were performed between 7:00 and 7:30 a.m. on the same days as blood sampling.
Time frame: Stage 1: baseline and Days 6, 12, and 18 of the intervention; Stage 2: baseline and Days 7 and 14 of the intervention, and 8, 14, and 42 days after the intervention.
Body fat percentage was assessed using a multi-frequency bioelectrical impedance analyzer (TANITA MC-780MA). Measurements were performed between 7:00 and 7:30 a.m. on the same days as blood sampling.
Time frame: Stage 1: baseline and Days 6, 12, and 18 of the intervention; Stage 2: baseline and Days 7 and 14 of the intervention, and 8, 14, and 42 days after the intervention.
Fat mass was assessed using a multi-frequency bioelectrical impedance analyzer (TANITA MC-780MA). Measurements were performed between 7:00 and 7:30 a.m. on the same days as blood sampling.
Time frame: Stage 1: baseline and Days 6, 12, and 18 of the intervention; Stage 2: baseline and Days 7 and 14 of the intervention, and 8, 14, and 42 days after the intervention.
Fat-free mass was assessed using a multi-frequency bioelectrical impedance analyzer (TANITA MC-780MA). Measurements were performed between 7:00 and 7:30 a.m. on the same days as blood sampling.
Time frame: Stage 1: at baseline and on Days 6, 12, and 18 of the intervention; Stage 2: at baseline, on Days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Total body water was assessed using a multi-frequency bioelectrical impedance analyzer (TANITA MC-780MA). Measurements were performed between 7:00 and 7:30 a.m. on the same days as blood sampling.
Poznan University of Physical Education
Other
The Effects of Live High-train Low on EPO, VEGF, and Hematological Variables in Elite Rowers
Acronym: IHOBMPBR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07341165
Behavior, Exercise
Louvain-la-Neuve, Belgium
View Trial DetailsNCT01614119
Behavior, Brain Diseases
Grenoble, France
View Trial DetailsNCT06472427
Acid-Base Imbalance, Acidosis
Leuven, Vlaams-Brabant, Belgium
View Trial DetailsNCT04739904
Behavior, Female Urogenital Diseases and Pregnancy Complications
Ljubljana, Slovenia
View Trial Details